NCT01625936View on ClinicalTrials.gov

CRLX101 Plus Bevacizumab in Advanced RCC

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

July 1, 2017

Study Completion Date

July 16, 2018

Conditions
Renal Cell Carcinoma
Interventions
DRUG

CRLX101 (Cerulean)

CRLX101 is an innovative tumor-targeting nanopharmaceutical.

DRUG

Bevacizumab

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT01625936 - CRLX101 Plus Bevacizumab in Advanced RCC | Biotech Hunter | Biotech Hunter